FML (fluorometholone) by AbbVie is corticosteroid hormone receptor agonists [moa]. First approved in 1972.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
FML (fluorometholone) is a topical ophthalmic corticosteroid suspension approved in 1972 for treating inflammatory conditions of the eye. It works by binding to corticosteroid hormone receptors to suppress inflammation and immune response in ocular tissues. This small-molecule steroid is administered as drops directly to the eye.
As a legacy product approaching loss of exclusivity with moderate competitive pressure, FML brand teams are likely focused on margin defense and transition planning rather than growth investment.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on FML offers limited career growth given the product's LOE trajectory and minimal linked job openings; roles focus on defending market share and optimizing commercial operations. This is primarily a legacy product assignment suitable for professionals managing mature portfolio brands or seeking stable, lower-intensity commercial work.
Worked on FML at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.